ストックスクリーナーアプリを入手
1.74
1.10%
-0.02
前日終値:
$1.76
開ける：
$1.7
24時間の取引高:
252.42K
Relative Volume:
0.71
時価総額：
$48.79M
収益：
-
当期純損益:
$-64.47M
株価収益率:
-0.2813
EPS:
-6.1852
ネットキャッシュフロー:
$-52.33M
1週間 パフォーマンス:
+3.61%
1か月 パフォーマンス:
-31.47%
6か月 パフォーマンス:
-63.89%
1年 パフォーマンス:
-92.03%
1日の値動き範囲:
$1.68
$1.7944
1週間の範囲:
$1.63
$1.97
52週間の値動き範囲:
$1.56
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
名前
Jasper Therapeutics Inc
セクター
電話
(650) 549-1400
住所
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.7434 | 49.25M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.11 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.62 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.90 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.89 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.18 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-09-09 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-08 | 開始されました | BTIG Research | Buy |
| 2024-06-27 | 開始されました | Stifel | Buy |
| 2024-05-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-03 | 開始されました | Evercore ISI | Outperform |
| 2024-03-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-18 | 開始されました | TD Cowen | Outperform |
| 2023-08-11 | 開始されました | CapitalOne | Overweight |
| 2022-02-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Credit Suisse | Outperform |
| 2021-10-21 | 開始されました | William Blair | Outperform |
| 2021-10-20 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-13 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Jasper Therapeutics Inc (JSPR) 最新ニュース
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Investor Alert: Deadline in Lawsuit on November 18, 2025 - openPR.com
DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, - GlobeNewswire
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR - GlobeNewswire Inc.
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Bank of Montreal Can Has $878,000 Stock Position in Jasper Therapeutics, Inc. $JSPR - Defense World
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025JSPR - MarketScreener
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
RBC Capital Maintains Jasper Therapeutics (JSPR) Sector Perform Recommendation - Nasdaq
Jasper Therapeutics stock price target lowered to $4 at RBC on BEACON concerns - Investing.com Canada
A look into Jasper Therapeutics Inc (JSPR)’s deeper side - Setenews
Get in on Rani Therapeutics Holdings Inc’s (RANI) buy-in window today! - setenews.com
RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk - MarketScreener
Jasper Therapeutics Reports Q3 2025 Financial Results - TipRanks
JSPR DEADLINE ALERT: ROSEN, A TOP-RANKED LAW FIRM, - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29) - TipRanks
Jasper Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report | JSPR SEC FilingForm 10-Q - Stock Titan
Jasper Therapeutics Q3 loss smaller than estimates - MarketScreener
[8-K] Jasper Therapeutics, Inc. Reports Material Event | JSPR SEC FilingForm 8-K - Stock Titan
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Jasper Therapeutics Faces Legal Storm Amid Clinical Trial Setbacks - Ad-hoc-news.de
JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Jasper Therapeutics - MarketScreener
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics Slides As Insider Purchases Lose Another US$89k - simplywall.st
Jasper Therapeutics Inc (JSPR) 財務データ
収益
当期純利益
現金流量
EPS
Jasper Therapeutics Inc (JSPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Option Exercise |
7.10 |
900 |
6,390 |
25,909 |
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):